Intensity Therapeutics and The Swiss Group for Clinical Cancer Research SAKK to Conduct a Ph 2 Randomized Trial in Early-Stage Breast Cancer in Europe for INT230-6 May 14, 2024
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer May 14, 2024
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies May 14, 2024
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer May 7, 2024
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology May 7, 2024
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib May 7, 2024
Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines based on Activation Lethality platform May 7, 2024
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline May 7, 2024
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs) May 1, 2024
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 + KEYTRUDA May 1, 2024
Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors May 1, 2024
Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines May 1, 2024
Ono Enters into a Collaboration Agreement with PRISM BioLab to Generate Novel Drug Candidates in the Oncology Area May 1, 2024
$15 million CIRM Grant Supports the Ongoing Ph 1 TRAVERSE Trial of ALLO-316 in Patients with Advanced or Metastatic RCC May 1, 2024
GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251 Against IGSF8, in Combination with KEYTRUDA April 23, 2024
Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic April 23, 2024
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR medicine SNIPR001 into clinical trials in haematological cancer patients April 23, 2024
Arvinas and Novartis to Develop and Commercialize PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer April 16, 2024
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated April 16, 2024
OSE Immunotherapeutics Receives €8.4 M in Public Funding for Registrational Ph 3 Trial of Cancer Vaccine Tedopi® in Lung Cancer April 16, 2024
